• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes therapy >Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide?1 Receptor Agonists in Chinese Patients with Type?2 Diabetes Mellitus
【24h】

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide?1 Receptor Agonists in Chinese Patients with Type?2 Diabetes Mellitus

机译：胰高血糖素肽的心血管结果试验结果的概括性？1型糖尿病患者的胰腺炎患者1个受体激动剂

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionThis study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide?1 receptor agonists (GLP-1?RAs) to Chinese patients with type?2 diabetes mellitus (T2DM).MethodsThe 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China ( n =?25,411), was examined for eligibility of enrollment in four GLP-1?RAs CVOTs (Dulaglutide-REWIND, Exenatide-EXSCEL, Liraglutide-LEADER, and Semaglutide-SUSTAIN-6). We first estimated the proportion of 3B population who would meet the six inclusion and exclusion (I/E) criteria, namely age, hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), history of cardiovascular disease (CVD), and antidiabetic medication, in each CVOT. Then we compared 11 baseline characteristics, namely age, gender, duration of diabetes, HbA1c, BMI, eGFR, history of CVD, prior myocardial infarction (MI), low-density lipoprotein cholesterol (LDL-c), diastolic blood pressure (DBP), and systolic blood pressure, between the population in each CVOT and the 3B population. Lastly, we estimated the proportion of 3B population that matched the characteristics in each CVOT population.ResultsOn the basis of the I/E criteria, 31.1% of the 3B population would have been eligible for enrollment in REWIND, 15.0% for SUSTAIN-6, 12.9% for LEADER, and 11.3% for EXSCEL. On the basis of the baseline characteristics, REWIND most closely matched the 3B population on gender, duration of diabetes, HbA1c, DBP, LDL-c, history of CVD, and prior MI. The proportion of 3B population matching on at least eight or at least ten baseline characteristics with CVOT populations was highest for REWIND compared to other CVOTs.ConclusionAmong the four GLP-1?RA CVOTs, the REWIND trial using once-weekly dulaglutide is most generalizable to Chinese patients with T2DM.Trial RegistrationTrial registration: NCT01128205 ( www.clinicaltrials.gov ).
机译：介绍本研究旨在探讨胰高血糖素肽的心血管结果试验（CVOTS）结果的概括性Δ1受体激动剂（GLP-1？RAS）对中国型患者（T2DM）.Methodsthe 3B（血液）葡萄糖，血压和血脂）人群，中国T2DM的国家代表性患者（n =？25,411），用于四个GLP-1的招生资格（Dulaglutide-Rewind，Exenatide-Excels ，丽格拉特德 - 领导者和半蛋白质持续6）。首先估计3B人口的比例，他们将满足六个包含和排斥（I / E）标准，即年龄，血红蛋白A1C（HBA1C），体重指数（BMI），估计肾小球过滤率（EGFR），心血管病史疾病（CVD）和抗糖尿病药物，在每种CVOT中。然后我们比较11个基线特征，即年龄，性别，糖尿病持续时间，HBA1c，BMI，EGFR，CVD的历史，先前心肌梗塞（MI），低密度脂蛋白胆固醇（LDL-C），舒张压血压（DBP）和收缩压，在每种CVOT和3B人群中的群体之间。最后，我们估计3B人口比例与每个CVOT人口中的特征相匹配。评估I / E标准的基础，3B人口的31.1％有资格参加倒带，持续6.0％，持续15.0％，领导者12.9％，excel的11.3％。在基线特征的基础上，倒盘最接近与性别，糖尿病持续时间，HBA1C，DBP，LDL-C，CVD历史和先前MI的患者最紧密匹配3B人口。与其他CVOTS相比，至少八个或至少十个基线特征与CVOT群体的3B人口匹配的比例最高，对于倒盘，对于其他CVOTS，FOURUSISMONG四个GLP-1？RA CVOTS，使用一次每周杜拉格拉蛋白质的倒带试验最普遍中国患有T2DM的患者.TRIAL RodalyTrial注册：NCT01128205（www.clinicaltrials.gov）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号